NCT04796831View on ClinicalTrials.gov

A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

April 26, 2021

Primary Completion Date

June 11, 2021

Study Completion Date

June 11, 2021

Conditions
Healthy Subjects
Interventions
DRUG

Quizartinib dihydrochloride

Single oral dose of 60 mg quizartinib (2 x 30 mg tablets)

DRUG

14C-Quizartinib solution for infusion

50 μg solution for infusion containing NMT 22.84 kBq 14C in 5 mL; administered once as a 15-minute infusion

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

Daiichi Sankyo

INDUSTRY

NCT04796831 - A Study to Determine the Absolute Oral Bioavailability of Quizartinib Using a Radiolabeled Microtracer in Healthy Subjects | Biotech Hunter | Biotech Hunter